secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2024-04-11T23:59:59+00:00
Accession:  0000950170-24-043532
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel Therapeutics receives FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer
--------------------------------------------------------------------------------

- FDA granted Orphan Drug Designation for CAN-2409 (multimodal immunotherapy) in pancreatic cancer.
- Fast Track Designation also previously granted; both designations support development.
- Phase 2 data showed median OS 28.8 mo (CAN-2409+SoC) vs 12.5 mo (SoC alone); 24-mo survival 71.4% vs 16.7%.
- No new safety signals; CAN-2409 generally well tolerated with no pancreatitis or DLTs.
- Orphan Drug status provides tax credits, fee waivers, and 7-year market exclusivity if approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000095017024043532/0000950170-24-043532-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000095017024043532/cadl-20240411.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-043532

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer